Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
4.775
+0.075 (1.60%)
At close: Jun 26, 2026, 4:00 PM EDT
4.750
-0.025 (-0.52%)
After-hours: Jun 26, 2026, 4:01 PM EDT
Lexeo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
59
Market Cap
374.94M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 654.00K | -1.00M | -60.53% |
| Dec 31, 2021 | 1.66M | 1.14M | 219.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 227.18M |
| Vanda Pharmaceuticals | 217.78M |
| Enanta Pharmaceuticals | 69.21M |
| Fennec Pharmaceuticals | 51.00M |
| OmniAb | 28.94M |
| X4 Pharmaceuticals | 9.01M |
| Upstream Bio | 3.32M |
| Compass Therapeutics | 850.00K |
LXEO News
- 1 day ago - Lexeo Therapeutics Transcript: AGM 2026 - Transcripts
- 1 day ago - Lexeo Therapeutics price target lowered to $9 from $12 at JPMorgan - TheFly
- 9 days ago - Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia - GlobeNewsWire
- 11 days ago - Lexeo Therapeutics Transcript: Investor update - Transcripts
- 11 days ago - Lexeo Therapeutics Slides: Investor update - Filings
- 11 days ago - Lexeo Therapeutics Press release: Investor update - Filings
- 11 days ago - Lexeo finalizes SUNRISE-FA 2 pivotal trial protocol, statistical analysis plan - TheFly
- 11 days ago - Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia - GlobeNewsWire